VIDEO: Targeted therapies show ‘dramatic activity’ in cholangiocarcinoma

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

We followed this disease going back to 2010 when the first established regimen was just chemotherapy with gemcitabine cisplatin, and a lot has happened since then. We've had, now we have about six FDA approvals for disease specific FDA approvals with several NCCN designations just since 2020. So there's been a lot of activity, particularly in the realm of targeted therapies for this disease. Obviously, immunotherapy also has become part of the frontline standard of care in combination with chemotherapy. But in the second line and beyond, we've seen a dramatic activity in terms of targeted therapy with both tumor specific approval and then tumor agnostic approvals.